Agenus Inc. · NASDAQ:AGEN

Agenus — Corporate Update (May 2021)

6 slides from Agenus's corporate update, May 18, 2021

1. Slide 1: May 2021

   May 2021

2. Slide 2: Forward-Looking Statements

   Forward-Looking Statements This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus and AgenTus' clinical development and regulatory plans and timelines for product candidates incl

3. Slide 3: Agenus / BMS Collaboration Highlights

   Agenus / BMS Collaboration Highlights Fc-enhanced bispecific anti-TIGIT program AGEN1777 • Upfront $200 million cash payment • Milestones up to $1.36 billion • Double-digit royalties up to mid-teens percent; up to low twenties percent with co-funding • Retained ability to conduct combination studies

4. Slide 4: AGEN1777: Differentiated Anti-TIGIT MOA

   AGEN1777: Differentiated Anti-TIGIT MOA Optimized front end Benefits High binding affinity to TIGIT and a T/NK cell inhibitory receptor IMMUNE ACTIVATION Novel Fc-mechanism promotes better T cell and NK cell activation1 Fc-enhanced back end SINGLE AGENT ACTIVITY AGEN1777 Novel Fc-mechanism promotes

5. Slide 5: 2021 Focus

   2021 Focus • AGEN1181 registrational program in colon cancer • Advance clinical programs for iNKTs in COVID and cancer • Advance VISION program to facilitate discovery and clinical development • Obtain balstilimab monotherapy approval 5 The agreement is subject to clearance under the Hart-Scott-Rodi

6. Slide 6: ogenus

   ogenus

Agenus — Corporate Update (May 2021) on 6ix